Accord EMENA Chief Says Industry Is Pushing Back On Pressures
Inflation, Pricing Constraints And Shortages Follow Fallout From Pandemic
Amid continuing cost inflation, downwards pressure on prices, industry shortages and other supply-chain disruptions, Paul Tredwell – Accord’s executive vice-president for the Europe, Middle East and North Africa region – talks about how the off-patent industry is seeking to improve its operating environment.
You may also be interested in...
Looking back over the second quarter of 2023, Generics Bulletin executive editor Dave Wallace picks out highlights from April to June that include strategic updates from some of the off-patent industry’s biggest players, several exclusive interviews, and the build-up to the second wave of biosimilar competition to Humira in the US.
With Accord boasting a broad portfolio that encompasses generics, biosimilars, hybrid medicines and specialty products, Paul Tredwell – the firm’s executive vice-president for the Europe, Middle East and North Africa region – explains how this gives the company a unique position in the market.
Responding to shortages of antibiotics seen around the world, the IGBA has insisted that the generics industry is working to address spikes in demand and has set out a series of recommendations to mitigate the situation. Meanwhile, US association the AAM has countered suggestions that supply issues are due to a “broken generic drug market.”